Longevity Biotech wins US patent for hybridtide platform technology for stabilized peptide therapeutics.
M2 PHARMA-October 12, 2017-Longevity Biotech wins US patent for hybridtide platform technology for stabilized peptide therapeutics
(C)2017 M2 COMMUNICATIONS
Biopharmaceutical company Longevity Biotech Inc (LBT) reported on Wednesday the receipt of the patent from the US Patent and Trademark Office (USPTO) for its hybridtide platform technology.
The US patent, which has been assigned the No. 9,782,454, covers the hybridtide platform technology, which is a revolutionary peptide technology originally developed in the academic laboratory of co-founder Professor Sam Gellman, Ph.D. at the University of Wisconsin and exclusively licensed to the company.
Additionally, the company's hybridtide technology has been applied to numerous targets including LBT-3627 for Parkinson's disease and LBT-6030 for type 2 diabetes.
According to the company, the hybridtide technology allows for the creation of synthetic molecules with dramatically increased durability and stability relative to conventional peptides. The hybridtides readily mimic the structures of natural peptides and small proteins, retaining potency and specificity, while improving the overall product profile.
In conjunction, the hybridtides are differentiated from peptides generated via other stabilisation technologies, including stapling or macrocyclization, as the changes are made to the interior of the molecules rather than the surface, concluded the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Neuronetics to sell and distribute NeuroStar Advanced Therapy system for Major Depressive Disorder (MDD) in Japan upon Shonin approval.|
|Next Article:||Beacon Health Options elects Michael Ramseier as EVP & market president.|